BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Eli  Lilly  Nederland  B.V.  submitted  on  31  May  2001  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
FORSTEO,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:   Dr I. Hudson 
Co-Rapporteur:  Dr E. Abadie 
Scientific Advice: 
The company Eli Lilly Nederland B.V. received Scientific Advice from the CPMP on 22 April 1999. 
The Scientific Advice pertained to IV of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 19 June 2001 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
13 September 2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP 
members on 12 September 2001. 
During  the  meeting  on  16  -  18  October  2001,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the company. The final consolidated List of Questions was sent to the 
company on 18 October 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
16 July 2002.  
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 3 September 2002.  
During the meeting on 17 – 19 September 2002 the CPMP adopted a list of outstanding issues 
to  be  addressed  by  the  company  in  writing.  The  list  of  outstanding  issues  was  sent  to  the 
company on 20 September 2002.  
The company provided written information on these outstanding issues to all CPMP members 
on 16 October 2002. The Rapporteur/Co-Rapporteurs’ joint review on the responses to the list 
of outstanding issues was circulated to all CPMP members on 7 November 2002. 
During the CPMP meeting on 19 – 21 November 2002, outstanding issues were addressed by 
the company during a hearing before the CPMP. 
During  the  meeting  on  17  –  18  December  2002  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to FORSTEO on 18 December 2002. 
In  February  2003,  the  European  Commission,  during  the  Standing  Committee  phase,  referred 
the  CPMP  opinion  back  to  the  CPMP  since  according  to  Article  51(1)(a)  all  batch  release 
testing has to be performed in the EU. 
1/2
EMEA 2004 
 
 
 
 
 
 
 
 
• 
• 
During the meeting on 18 - 19 March 2003 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  revised  positive  opinion  for 
granting a Marketing Authorization to FORSTEO on 19 March 2003. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 10 June 2003. 
2/2
EMEA 2004 
 
 
  
